FDA Raises Serious Doubts Over Replimune’s RP1 Melanoma Therapy Ahead of Key Panel
FDA briefing docs criticize Replimune’s RP1 trial data, raising doubts over effectiveness and sending shares down ahead of Thursday’s panel.
/ 60 items
#XY News-Driven Stocks↓
Curium in Advanced Talks to Acquire Lantheus for About $7 Billion
Curium is in advanced talks to buy Lantheus for ~$7B ($102/share + $12.50 CVRs). Announcement possible soon; no final deal confirmed yet.
Piper Sandler: Intuitive Surgical Still Dominant in Soft-Tissue Robotics Despite J&J’s Ottava
Piper sees Intuitive Surgical staying ahead in robotic surgery, with strong growth potential despite rising competition.
Rhode Island’s Most Wanted Fugitive Lived as Biotech CMO — Arrested After 21 Years on the Run
Ronald Fischer, convicted of sexual assault, evaded justice for over two decades while living under the alias Richard Graydon as CMO of Immix Biopharma.
Abivax Re-Engages Centerview as It Eyes Major Pharma Partnerships After $874M Raise
Abivax has resumed partnership talks with major pharma companies via Centerview Partners while preparing a potential independent U.S. launch of obefazimod.
Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.